Coagulation-Fibrinolysis System and Postoperative Outcomes of Patients With Chronic Thromboembolic Pulmonary Hypertension
|
|
- Emil Jackson
- 6 years ago
- Views:
Transcription
1 970 KATO F et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society Pulmonary Circulation Coagulation-Fibrinolysis System and Postoperative Outcomes of Patients With Chronic Thromboembolic Pulmonary Hypertension Fumiaki Kato, MD; Nobuhiro Tanabe, MD, PhD; Keiichi Ishida, MD, PhD; Rika Suda, MD; Ayumi Sekine, MD, PhD; Rintaro Nishimura, MD, PhD; Takayuki Jujo, MD, PhD; Toshihiko Sugiura, MD, PhD; Seiichiro Sakao, MD, PhD; Koichiro Tatsumi, MD, PhD Background: The postoperative changes in the coagulation-fibrinolysis system and the association between the system and postoperative course of patients with chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary endarterectomy (PEA) remain unclear. Methods and Results: Between 1986 and 2013, 117 patients (55.1±11.2 years, preoperative mean pulmonary arterial pressure 46.5±10.5 mmhg) underwent PEA, and 15 patients died during the perioperative period. We studied the association between the preoperative coagulation-fibrinolysis markers and surgical outcomes of all patients, and the long-term outcomes of the 102 survivors from the date of PEA. We also investigated the postoperative changes in coagulation-fibrinolysis markers and their association with residual pulmonary hypertension (PH) in 20 consecutive patients. Only an elevated factor VIII level was associated with perioperative death. Thrombomodulin and plasminogen values were significantly increased after PEA. Univariate logistic regression analysis revealed that D-dimer positivity at follow-up was a risk factor for residual PH. Patients with both an elevated fibrinogen level ( 291 mg/dl [median]) and decreased plasminogen activity (<100% [median]) had significantly worse disease-specific survival than the other patients (5-year disease-specific survival: 84.0% vs. 100%, respectively; P= [log-rank test]). Conclusions: Preoperatively high fibrinogen and low plasminogen values in patients with CTEPH are associated with poor long-term postoperative outcome. PEA benefited not only the pulmonary hemodynamics but also the coagulation-fibrinolysis system of patients. (Circ J 2016; 80: ) Key Words: Chronic thromboembolic pulmonary hypertension; Fibrinogen; Plasminogen; Prognosis; Pulmonary endarterectomy Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by thrombotic obstruction of the pulmonary arteries and progressive pulmonary hypertension (PH). Pulmonary endarterectomy (PEA) offers symptomatic and prognostic improvement and is a curative treatment for patients with CTEPH. 1 3 Pre- and postoperative hemodynamic parameters have been used to predict the outcomes of patients with operative CTEPH, 4 6 but it is doubtful whether hemodynamic parameters alone can predict the outcome of patients with CTEPH, which has the risk of clot formation. Editorial p 821 Increased coagulation and decreased fibrinolysis are thought to be involved in the progression of CTEPH. Abnormalities in the coagulation-fibrinolysis system, including elevated levels of tissue type plasminogen activator, type 1 plasminogen activator inhibitor (PAI-1), and clotting factor VIII, and decreased thrombomodulin (TM) levels or activity, have been reported in patients with CTEPH Increased plasma TM levels after PEA have also been reported. 9 However, there have been few studies that have investigated whether the outcome of patients with CTEPH after PEA is related to abnormalities in the coagulation-fibrinolysis system. We previously reported that high plasma fibrinogen levels and low plasminogen activity were associated with poor longterm outcomes in medically treated patients with CTEPH. 11 Received November 13, 2015; revised manuscript received December 29, 2015; accepted January 14, 2016; released online February 16, 2016 Time for primary review: 13 days Department of Respirology (F.K., N.T., R.S., A.S., R.N., T.J., T.S., S.S., K.T.), Department of Advanced Medicine in Pulmonary Hypertension (N.T., A.S., R.N., T.J.), Department of Cardiovascular Surgery (K.I.), Graduate School of Medicine, Chiba University, Chiba, Japan Mailing address: Fumiaki Kato, MD, Department of Respirology, Graduate School of Medicine, Chiba University, Inohana, Chuouku, Chiba , Japan. fumiakkato@chiba-u.jp ISSN doi: /circj.CJ All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 Coagulation and Fibrinolysis in Operative CTEPH 971 Patients with both a high fibrinogen level and low plasminogen activity particularly had extremely poor outcomes. Those results suggest that abnormalities of the coagulation-fibrinolysis system may be associated with poor outcomes, even in operative patients. However, the relationship of the coagulation-fibrinolysis system with the postoperative course of patients with operative CTEPH remains unclear. Therefore, we tested the following hypotheses: (1) abnormalities in the coagulation-fibrinolysis system are associated with early and long-term outcomes of patients with CTEPH after PEA, and (2) PEA has beneficial effects on the coagulation-fibrinolysis system. Methods Study Outline This was a retrospective study of patients with CTEPH who underwent PEA. The following 3 investigations were performed: (1) the relationship between coagulation-fibrinolysis markers and early and long-term outcomes (disease-specific and overall survival) after PEA; (2) changes in coagulationfibrinolysis markers between the time of diagnosis and the 1-year follow-up after PEA; (3) the relationship between coagulation-fibrinolysis markers and residual PH at the 1-year follow-up after PEA. Patients Between 1986 and 2013, 250 patients were diagnosed with CTEPH at Chiba University Hospital. CTEPH was defined as a mean pulmonary arterial pressure (mpap) 25 mmhg with a normal wedge pressure in patients with dyspnea on exertion for longer than 6 months. An additional requirement was segmental or larger defects on lung perfusion scans in patients with normal ventilation scans. Chronic thromboembolic findings were confirmed on pulmonary angiography. Patients were selected to undergo PEA, based on criteria that were slightly modified from those defined by Moser et al. 12 The study criteria were as follows: (1) mean mpap >30 mmhg, resulting in a calculated pulmonary vascular resistance (PVR) >300 dyne/s/cm 5 (3.75 Wood units [WU]), even after oral anticoagulant therapy for >6 months; (2) World Health Organization (WHO) functional class II; (3) thrombi accessible to current surgical techniques (located in main, lobar, or segmental arteries); and (4) absence of severe concomitant disease. There were 134 patients who fulfilled these criteria, consented to surgical therapy, and underwent PEA performed by experienced surgeons. The first 16 patients who underwent PEA via lateral thoracotomy and 1 patient with pneumonia at diagnosis were excluded. Finally, a total of 117 patients treated since 1990 were investigated in this study. All 117 patients underwent assessments of venous blood samples during diagnostic catheterization, and those data were used for evaluating long-term outcomes. A total of 15 patients died during the perioperative period (within 1 month after PEA), and were excluded from the long-term analysis of the surviving patients (disease-specific survival), resulting in 102 patients who were studied to determine disease-specific survival; 90 of these 102 patients underwent right heart catheterization within 3 months after PEA. All 102 patients received warfarin; 24 of the 102 patients were preoperatively treated with pulmonary vasodilators at the time of diagnosis (epoprostenol sodium, n=1; beraprost, n=17; bosentan, n=7; ambrisentan, n=1; sildenafil, n=6; tadalafil, n=4), and 28 patients were treated with pulmonary vasodilators during the follow-up period because of progression of Table 1. Baseline Characteristics of All Patients at Diagnosis of CTEPH (n=117) Mean ± SD, % or n Median n 117 Age (years) 55.1±11.2 Sex (male %) 37.6 Coagulopathy (%) 44.2 APA positive (%) 27.1 WHO class III or IV (%) 76.1 D-dimer 1 μg/ml (%) 37.6 Fibrinogen (mg/dl) 305.4± TAT 3.0 ng/ml (%) 11.9 Factor VIII (%) 145.4±72.8 TM (FU/ml) 5.7±2.9 Plasminogen (%) 98.3± PIC (μg/ml) 0.9±0.4 PAI-1 (ng/ml) 25.5±11.9 α2pi (%) 103.0±15.6 TPAIC (ng/ml) 13.4±7.8 BNP (pg/ml) 230.2±260.3 PaO2 (mmhg) 50.4±20.2 Group A (%) 17.1 mpap (mmhg) 46.5±10.5 Cardiac index (L/min/m 2 ) 2.6±0.7 PVR (WU) 10.9±4.4 Coagulopathy was defined as APA positivity, deficiencies in protein C/S and antithrombin, and thrombocytosis. Group A consisted of patients with both high fibrinogen ( median level of 291 mg/dl) and low plasminogen activity (<median activity of 100%) at diagnosis. α2pi, α2-plasmin inhibitor activity; APA, antiphospholipid antibody; BNP, brain natriuretic peptide; CTE(PH), chronic thromboembolic (pulmonary hypertension); Factor VIII, clotting factor VIII; fibrinogen, plasma fibrinogen; mpap, mean pulmonary artery pressure; PAI-1, plasminogen activator inhibitor type 1; PIC, plasmin-α2 plasmin inhibitor complex; PVR, pulmonary vascular resistance; TAT, thrombin-antithrombin complex; TM, thrombomodulin; TPAIC, tissue plasminogen activator/pai-1 complex; WHO, World Health Organization; WU, Wood units. CTEPH (epoprostenol sodium, n=1; beraprost, n=12; bosentan, n=4; ambrisentan, n=1; sildenafil, n=10; tadalafil, n=4; riociguat, n=2). For the evaluation of changes between the time of diagnosis and the 1-year follow-up, a retrospective review revealed that 20 of 117 patients had undergone assessments of pulmonary hemodynamic parameters and coagulation-fibrinolysis markers during that period; 5 patients with mpap >30 mmhg or requiring additional use of pulmonary vasodilators were identified as having residual PH. 13,14 Pulmonary vasodilators included beraprost (n=7), bosentan (n=4), ambrisentan (n=1), sildenafil (n=2) and tadalafil (n=3) at diagnosis, and bosentan (n=1), sildenafil (n=1), and tadalafil (n=1) at the time of 1-year follow-up because of progression of CTEPH. This study was approved by the Ethics Committee of Chiba University and written informed consent was given by each patient before catheterization. Surgical Procedure PEA was performed via median sternotomy with periods of deep hypothermic circulatory arrest, in accordance with the standardized technique described previously. 4,14 An inferior vena cava filter was inserted in 99 of 117 patients preoperatively.
3 972 KATO F et al. Table 2. Preoperative Parameters of CTEPH Patients Who Died Perioperatively and Patients Who Survived Perioperative period Died Survived P value n Age (years) 52.3± ±11.2 NS Sex (male %) NS Coagulopathy (%) NS APA positive (%) NS WHO class III or IV (%) NS D-dimer 1 μg/ml (%) NS Fibrinogen (mg/dl) 306.3± ±72.3 NS TAT 3.0 ng/ml (%) NS Factor VIII (%) 213.0± ± TM (FU/ml) 5.0± ±3.0 NS Plasminogen (%) 98.2± ±15.9 NS PIC (μg/ml) 0.9± ±0.4 NS PAI-1 (ng/ml) 33.8± ±10.6 NS α2pi (%) 100.6± ±15.9 NS TPAIC (ng/ml) 16.1± ±7.5 NS BNP (pg/ml) 293.1± ±256.9 NS PaO2 (mmhg) 54.3± ±20.5 NS Group A (%) NS mpap (mmhg) 52.9± ± Cardiac index (L/min/m 2 ) 2.3± ±0.7 NS PVR (WU) 14.3± ± NS, not significant. Other abbreviations as in Table 1. Data Acquisition Venous blood samples were collected during right heart catheterization at diagnosis or follow-up. Samples were collected in 3.13% trisodium citrate tubes, and plasma was obtained by centrifuging the tubes at 1,880 g for 10 min at 25 C. Plasma fibrinogen concentration and clotting factor VIII activity were measured by light-scattering photometry. Plasma plasminogen and α2-plasmin inhibitor (α2pi) activities were measured by a synthesized substrate assay. D-dimer concentration was measured by immune nephelometry. Plasma concentrations of TM, tissue plasminogen activator-plasminogen activator inhibitor-1 complex (TPAIC), thrombin-antithrombin complex (TAT), and plasmin-α2pi complex (PIC) were measured by enzyme-linked immunosorbent assays. Plasma PAI-1 concentration was measured by a latex photometric immunoassay. Excluding 7 patients who did not have fibrinogen or plasminogen measured, patients were divided into 2 groups based on the median values of 110 patients for plasma fibrinogen concentration (median=291 mg/dl) and plasma plasminogen activity (median=100%). Patients with both a high fibrinogen level and a low plasminogen activity were defined as Group A and all others as Group B, as previously reported. 11 Pressure measurements included mpap and pulmonary arterial wedge pressure (PAWP). Cardiac output (CO) and cardiac index (CI) were estimated using the thermodilution method. PVR was calculated as follows: PVR=(mPAP PAWP)/CO. Following catheterization, pulmonary angiography was performed using Berman catheters to determine operability. Patients were diagnosed with coagulopathy if they had positive antiphospholipid antibody, deficiencies in protein C/S and antithrombin, and thrombocytosis. Comparison of Preoperative Parameters Between Perioperative Survivors and Non-Survivors In all 117 patients, the clinical and coagulation-fibrinolysis parameters of patients who died during the perioperative period (within 1 month after PEA) and those who survived were compared. Changes in Coagulation-Fibrinolysis Markers Determined Before and After PEA For 20 patients who had 1-year follow-up data, clinical parameters such as pulmonary hemodynamics and the coagulationfibrinolysis parameters determined at the time of diagnosis were compared with those determined at follow-up after PEA. The clinical and coagulation-fibrinolysis parameters determined at the time of diagnosis were compared with those determined within 3 months after PEA in some patients (n=48). Assessment of Risk for Residual PH For the same 20 patients who had 1-year follow-up data, the clinical and coagulation-fibrinolysis parameters determined at the time of diagnosis and at the 1-year follow-up were compared between patients with and without residual PH. Candidate risk factors for residual PH were evaluated by univariate logistic regression analysis. Hemodynamic parameters at the time of 1-year follow-up were not evaluated by univariate logistic regression analysis because residual PH was defined according to those parameters. Long-Term Survival Analysis Disease-specific survival and overall survival were calculated from the date of PEA. In April 2014, follow-up data were obtained from all 102 patients either by direct contact with patients or with their primary physicians: 89 patients survived
4 Coagulation and Fibrinolysis in Operative CTEPH 973 Table 3. CTEPH Patients Characteristics and Parameters Assessed at Diagnosis and 1-Year Follow-up (n=20) At diagnosis 1-year follow-up P value Age (years) 58.1±11.1 Sex (male %) 15.0 Coagulopathy (%) 45.0 APA positive (%) 25.0 WHO class III or IV (%) NS D-dimer 1 μg/ml (%) NS Fibrinogen (mg/dl) 288.8± ±64.0 NS TAT 3.0 ng/ml (%) NS Factor VIII (%) 105.4± ±43.6 NS TM (FU/ml) 4.8± ± Plasminogen (%) 100.0± ± PIC (μg/ml) 0.7± ±0.3 NS PAI-1 (ng/ml) 23.8± ±10.3 NS α2pi (%) 100.5± ±10.7 NS TPAIC (ng/ml) 12.6± ±6.3 NS BNP (pg/ml) 162.8± ± PaO2 (mmhg) 57.0± ± Group A (%) NS mpap (mmhg) 43.1± ±8.5 < Cardiac index (L/min/m 2 ) 2.9± ±0.6 NS PVR (WU) 9.2± ±2.2 < Abbreviations as in Tables 1,2. to follow-up and 13 patients did not; 6 of the 13 died of CTEPH-associated right heart failure or sudden death and the other 7 were treated as censored cases (asphyxia, n=1; pneumonia, n=1; interstitial pneumonitis, n=1; cerebral hemorrhage, n=1; cerebral infarction, n=1; multiple organ failure, n=1; natural causes, n=1) for the assessment of disease-specific survival of the perioperative survivors. However, for overall survival analysis, the 7 patients were treated as event counts as well as perioperative deaths. Candidate predictive factors for disease-specific survival were evaluated by univariate Cox proportional hazards analysis and included age, sex, pulmonary hemodynamic parameters at diagnosis and immediately after PEA, use of pulmonary vasodilators, coagulation-fibrinolysis parameters, and Group A (vs. B), combined factors of plasma fibrinogen level 291 mg/dl and plasma plasminogen activity <100% (=Group A) vs. the others (Group B) as previously described. The disease-specific survival of the 98 patients who had preoperative data on fibrinogen and plasminogen were compared after stratification of the patients into Groups A and B. In addition, overall survival, which included perioperative death and death from causes other than CTEPH at follow-up, was compared in patients who had preoperative data on fibrinogen and plasminogen (n=110) and were also similarly stratified. Statistical Analysis The results are expressed as mean ± SD for continuous variables. Unpaired and paired continuous variables were analyzed using the Wilcoxon-Mann-Whitney test and the Wilcoxon signed-rank test, respectively. Categorical data were analyzed using the chi-square test. The Kaplan-Meier method was used to estimate disease-specific survival and overall survival, with the log-rank test used for comparisons. Univariate Cox proportional hazards analysis was used to evaluate prognostic factors. Univariate logistic regression analysis was used to evaluate risk factors for residual PH. A P-value <0.05 was considered significant. Statistical analysis was performed using JMP version 9.0 software (SAS Institute, Cary, NC, USA). Results Patients Characteristics at Diagnosis The baseline characteristics of the 117 patients who underwent PEA are listed in Table 1. The mean age at diagnosis was 55.1±11.2 years. Of the 117 patients, 44 (37.6%) were male and 73 were female. Most patients (76.1%) were classified as WHO functional class III at diagnosis. The mean baseline mpap, CI, and PVR were 46.5±10.5 mmhg, 2.6±0.7 L/min/m 2, and 10.9±4.4 WU, respectively. Postoperative Instability of Coagulation-Fibrinolysis Parameters The coagulation-fibrinolysis parameters of some patients (n=48) were determined within 3 months after PEA and compared with those parameters at diagnosis (Table S1). The positivity rates of D-dimer and TAT, factor VIII activity, and the concentrations of fibrinogen, TM and PIC were significantly increased after PEA. Relationship Between Preoperative Parameters and Perioperative Death The preoperative parameters of patients who died during the perioperative period and those who survived are shown in Table 2. Higher values of factor VIII (213.0±80.7 vs ±69.1%, P=0.0175), mpap (52.9±10.3 vs. 45.6± 10.2 mmhg, P=0.0102), and PVR (14.3±4.6 vs. 10.3±4.1 WU, P=0.0039) were observed in patients who died perioperatively compared with perioperative survivors, respectively.
5 974 KATO F et al. Table 4. CTEPH Patients Characteristics and Parameters Assessed at Diagnosis of Patients With and Without Residual PH at 1-Year Follow-up (n=20) Preoperative data 1-year residual PH ( ) n=15 (+) n=5 P value Age (years) 56.1± ±7.0 NS Sex (male %) NS Coagulopathy (%) NS APA positive (%) NS WHO class III or IV (%) NS D-dimer 1 μg/ml (%) NS Fibrinogen (mg/dl) 289.9± ±57.1 NS TAT 3.0 ng/ml (%) NS Factor VIII (%) 105.7± ±28.4 NS TM (FU/ml) 4.4± ±6.1 NS Plasminogen (%) 100.5± ±13.2 NS PIC (μg/ml) 0.7± ±0.1 NS PAI-1 (ng/ml) 25.2± ±5.0 NS α2pi (%) 99.4± ±6.8 NS TPAIC (ng/ml) 13.8± ±5.7 NS BNP (pg/ml) 106.5± ±411.1 NS PaO2 (mmhg) 57.5± ±8.7 NS Group A (%) NS mpap (mmhg) 39.5± ± Cardiac index (L/min/m 2 ) 2.8± ±0.7 NS PVR (WU) 8.2± ± Abbreviations as in Tables 1,2. Effects of PEA on the Coagulation-Fibrinolysis System and Other Parameters at Follow-up The coagulation-fibrinolysis parameters of 20 patients at the time of diagnosis and at the 1-year (12.9±1.6 months) followup after PEA are shown in Table 3. The mean age of these patients at diagnosis was 58.1±11.1 years, and there were more female than male patients. The mean baseline values of mpap, CI, and PVR were 43.1±10.6 mmhg, 2.9±0.7 L/min/m 2 and 9.2±3.9 WU, respectively. At the 1-year follow-up after PEA, mpap, PVR and brain natriuretic peptide (BNP) significantly increased and PaO2 significantly decreased. Regarding fibrinolytic parameters, TM concentration significantly increased from 4.8±3.3 FU/ml at baseline to 12.8±4.6 FU/ml at the 1-year follow-up (P=0.0002), and plasminogen activity also significantly increased from 100.0±15.0% to 105.9±16.1% (P=0.0312). There were no significant changes in the other markers of the coagulation-fibrinolysis system. The percentage of patients in Group A tended to reduce from 20.0% at base line to 5.0% at 1-year follow-up after PEA, but there was no significance. Risk for Residual PH at Follow-up The same 20 patients were analyzed for risk factors of residual PH at the 1-year follow-up; 5 of the 20 had residual PH and their preoperative and 1-year follow-up data were used for these analyses. There were no significant differences in coagulation-fibrinolysis parameters between the preoperative parameters of patients with and without residual PH at the 1-year follow-up (Table 4). Table 5A shows the postoperative parameters at 1-year follow-up of the patients with and without residual PH. Significantly increased values of BNP, mpap, and PVR, and a higher D-dimer positivity rate were observed in the patients with residual PH. Univariate logistic regression analysis revealed that D-dimer positivity and a high BNP level at follow-up were associated with risk for residual PH (Table 5B). Disease-Specific and Overall Survival and Prognostic Factors The baseline characteristics of all 102 perioperative survivors are shown in Table 6. The mean age at diagnosis was 55.5±11.2 years. Of the 102 patients, 35 (34.3%) were male and 67 were female. There were 74.5% of patients classified as WHO functional class III. The mean baseline values of mpap, CI, and PVR were 45.6±10.2 mmhg, 2.6±0.7 L/min/m 2, and 10.3±4.1 WU, respectively. Postoperative hemodynamic data were obtained for 85 of 102 patients within 3 months (1.38±0.44 months) after PEA. The mean postoperative values of mpap, CI, and PVR were 24.6±9.7 mm Hg, 3.1±0.6 L/min/m 2 and 3.9±2.7 WU, respectively. The mean observation period was 6.7±5.0 years. The 5-year disease-specific survival of all 102 patients who survived PEA was 97.3%. The characteristics of the 98 patients with preoperative data on fibrinogen and plasminogen who were stratified according to median fibrinogen and plasminogen values are shown in Table S2A. Group A (n=17 patients with increased fibrinogen and decreased plasminogen) had higher TPAIC levels than Group B (n=81) and all other patients (15.8±8.3 vs. 12.4±7.3 ng/ml, respectively; P=0.0288). Group A had a significantly worse 5-year disease-specific survival than Group B (84.0% vs. 100%, respectively; log-rank test P=0.0041; Figure A). Univariate Cox proportional hazards analysis revealed that older age, Group A (vs. B), higher postoperative mpap, and higher postoperative PVR were significant prognostic factors (Table 7).
6 Coagulation and Fibrinolysis in Operative CTEPH 975 Table 5. Residual PH at the 1-Year Follow-up (n=20), (A) CTEPH Patients Characteristics and Parameters Assessed at the 1-Year Follow-up of Patients With and Without 1-Year Residual PH, (B) Risk Factors for Residual PH at the 1-Year Follow-up (A) 1-year follow-up data 1-year residual PH ( ) n=15 (+) n=5 P value WHO class III or IV (%) NS D-dimer 1 μg/ml (%) Fibrinogen (mg/dl) 285.5± ±53.6 NS TAT 3.0 ng/ml (%) NS Factor VIII (%) 122.9± ±50.6 NS TM (FU/ml) 11.9± ±2.9 NS Plasminogen (%) 104.8± ±6.1 NS PIC (μg/ml) 0.7± ±0.3 NS PAI-1 (ng/ml) 20.8± ±9.3 NS α2pi (%) 100.9± ±14.1 NS TPAIC (ng/ml) 14.4± ±4.9 NS BNP (pg/ml) 44.7± ± PaO2 (mmhg) 74.5± ±24.3 NS Group A (%) NS mpap (mmhg) 20.7± ± Cardiac index (L/min/m 2 ) 2.8± ±0.5 NS PVR (WU) 2.7± ± (B) 1-year follow-up data Univariate logistic regression analysis OR 95% CI P value WHO class III or IV ( ) NS D-dimer 1 μg/ml 125,230,612 ( ) Fibrinogen ( ) NS TAT 3.0 ng/ml ( ) NS Factor VIII ( ) NS TM ( ) NS Plasminogen ( ) NS PIC ( ) NS PAI ( ) NS α2pi ( ) NS TPAIC ( ) NS BNP ( ) PaO ( ) NS Group A ( ) NS Continuous variables were indicated as per unit increase. Upper limit of CI for D-dimer could not be accurately calculated by the statistical software because the value was too high. Lower limit of CI for Group A (vs. B) could not be accurately calculated because the value was too low. CI, confidence interval; OR, odds ratio. Other abbreviations as in Tables 1,2. The 5-year overall survival rate of 110 patients including perioperative death and death from causes other than CTEPH at follow-up was 82.2%. Table S2B shows the characteristics of these patients stratified into Groups A (n=18) and B (n=92). Group A had significantly worse 5-year overall survival than Group B (73.2% vs. 86.2%, respectively; log-rank test P=0.0490; Figure B). The detailed causes of death of Group A were: disease-specific death (n=3, 16.7%), perioperative death (n=1, 5.6%) and other deaths (n=3, 16.7%), including cerebral hemorrhage (n=1), cerebral infarction (n=1) and multiple organ failure (n=1). For Group B, the causes of death were: disease-specific death (n=2, 2.2%), perioperative death (n=11, 12.0%) and other deaths (n=3, 3.3%), including interstitial pneumonitis (n=1), asphyxia (n=1), and natural causes (n=1) (data not shown). Discussion We found that the combination of high preoperative fibrinogen and low preoperative plasminogen values was a significant poor prognostic factor for postoperative CTEPH patients. In addition, we found that TM and plasminogen values were increased at follow-up after PEA; a high preoperative factor VIII value was associated with perioperative death; and D-dimer positivity at follow-up was a risk factor for residual PH. To our knowledge, this is the first study to show an association between the coagulation-fibrinolysis system and the long-term outcome of patients with CTEPH who undergo
7 976 KATO F et al. Table 6. Characteristics and Parameters Assessed at Diagnosis of CTEPH Patients Included in the Disease-Specific Survival Analysis Parameter Mean ± SD, % or n Median n 102 Data at diagnosis Age (years) 55.5±11.2 Sex (male %) 34.3 Coagulopathy (%) 44.9 APA positive (%) 28.0 WHO class III or IV (%) 74.5 D-dimer 1 μg/ml (%) 38.9 Fibrinogen (mg/dl) 305.3± TAT 3.0 ng/ml (%) 13.8 Factor VIII (%) 138.7±69.1 TM (FU/ml) 5.7±3.0 Plasminogen (%) 98.3± PIC (μg/ml) 0.9±0.4 PAI-1 (ng/ml) 24.8±10.6 α2pi (%) 103.3±15.9 TPAIC (ng/ml) 13.1±7.5 BNP (pg/ml) 222.4±256.9 PaO2 (mmhg) 49.9±20.5 Group A (%) 18.2 mpap (mmhg) 45.6±10.2 Cardiac index (L/min/m 2 ) 2.6±0.7 PVR (WU) 10.3±4.1 Data at follow-up within 3 months Postoperative mpap 24.6±9.7 Postoperative cardiac index 3.1±0.6 Postoperative PVR 3.9±2.7 Over follow-up period Use of pulmonary 29.8 vasodilators (%)* *Pulmonary vasodilators included epoprostenol sodium, beraprost, bosentan, ambrisentan, sildenafil, tadalafil, and riociguat. Abbreviations as in Tables 1,2. PEA, and to identify a risk factor for residual PH after PEA. Several issues must be considered when interpreting these results. Group A, which included patients with high preoperative fibrinogen levels ( 291 mg/dl) together with low preoperative plasminogen activity (<100%), as well as high postoperative mpap and high postoperative PVR, were associated with worse disease-specific survival after PEA for postoperative CTEPH. We previously reported that plasma fibrinogen and plasma plasminogen were independent prognostic factors in patients with medically treated CTEPH. 11 In addition, similar to this study, the combination of a fibrinogen level the median value of 291 mg/dl together with a plasminogen activity < the median of 101% was an extremely strong prognostic factor for survival in patients with medically treated CTEPH. 11 Although in this study, univariate analysis did not identify fibrinogen and plasminogen as significant predictors of disease-specific survival, high fibrinogen and low plasminogen levels tended to be associated with poor outcome. Taken together, the results of this and previous studies suggest that the long-term outcome of patients with CTEPH is likely to be affected by the coagulation-fibrinolysis system regardless of whether they are treated medically or surgically. Although the preoperative TPAIC levels in Group A were significantly higher than in Group B (Table S2A), univariate Cox proportional analysis did not identify TPAIC as a significant prognostic indicator of disease-specific survival (Table 7). Interestingly, the poor outcome of Group A was associated not only with disease-specific death but also with death from conditions other than CTEPH. The causes of nonspecific death in Group A included more cardiovascular disease and inflammatory disease. The chronic microvascular inflammation, as reflected by an increased plasma fibrinogen level, 15,16 might be associated with cerebrovascular events and multiple organ failure. In the present study, patients were classified into Group A or B, but patients could be further subdivided into 4 categories using median fibrinogen and plasminogen as cut-offs (subgroup 1, lower fibrinogen and higher plasminogen; subgroup 2, lower fibrinogen and lower plasminogen; subgroup 3, higher fibrinogen and higher plasminogen; subgroup 4, higher fibrinogen and lower plasminogen [=group A]). mpap, CI and PVR were compared in these 4 subgroups by Kruskal-Wallis test. Among these 4 groups, there was no significant difference in baseline hemodynamics (data not shown). The survival analyses were performed in perioperative survivors for disease-specific survival (Figure S1A) and in all patients for overall survival (Figure S1B). In these 2 additional analyses, no significant differences were observed. However, there was a tendency for survival rate to be highest in subgroup 1, intermediate in subgroups 2 and 3, and lowest in subgroup 4 in both analyses. Bonderman et al reported on prognostic factors other than hemodynamic parameters in patients with operative CTEPH. 17 They concluded that PEA, PVR, and associated medical conditions such as splenectomy, ventriculoatrial shunt for the treatment of hydrocephalus, permanent central intravenous lines, inflammatory bowel disease, and osteomyelitis were predictors of survival. We had only 1 patient with an associated medical condition (ulcerative colitis), and the patient was classified into Group B. However, there have not been any studies that have exhaustively investigated the association between the outcomes of surgically treated patients with CTEPH and the parameters of the coagulation-fibrinolysis system. Our study provides evidence that coagulation-fibrinolysis parameters, especially fibrinogen and plasminogen values, may be useful for predicting the long-term outcomes of patients after PEA. Coagulation is promoted by the conversion of fibrinogen into fibrin by thrombin. 18 Therefore, an altered plasma fibrinogen level is considered to be an indicator of coagulopathy. Plasminogen is the inactive form of plasmin, which resolves fibrin blood clots. Therefore, altered plasminogen activity indicates aberrant fibrinolysis. 19 Increased coagulation and decreased fibrinolysis may directly contribute to the progression of CTEPH, and also may result in death unrelated to CTEPH, such as death from a cerebrovascular event or renal or liver failure. The beneficial effect of PEA on the fibrinolysis system was seen at follow-up in this study. The elevated TM levels after PEA were similar to the results of a previous study reported by Sakamaki et al. 9 Additionally, this is the first study to report elevation of plasminogen after PEA. Our study, however, did not investigate the mechanisms of the increase in plasma TM and plasminogen values at follow-up after PEA. A hypothetical mechanism is that thrombi that result in consumed plasmin could be reduced by PEA, resulting in increased plasminogen. Considering that plasminogen has been reported to decrease
8 Coagulation and Fibrinolysis in Operative CTEPH 977 Figure. (A) Kaplan-Meier estimates of 5-year disease-specific survival in patients who survived pulmonary endarterectomy. Patients were classified by median plasma fibrinogen level and plasminogen activity. Group A (red), 17 patients with both high fibrinogen and low plasminogen; Group B (blue), the other 81 patients. Group A had significantly worse disease-specific survival than Group B (5-year survival, 84.0% vs. 100%, respectively; P=0.0041, log-rank test). (B) Kaplan-Meier survival estimates of overall 5-year survival of all patients with chronic thromboembolic pulmonary hypertension, including patients who died during the perioperative period (within 1 month after pulmonary endarterectomy) and who died from other causes. Patients were classified into Group A (red, n=18) or Group B (blue, n=92) based on the same criteria as in (A). Group A had significantly worse overall survival than Group B (5-year survival 73.2% vs. 86.2, respectively; P=0.0490, log-rank test). with age, 11,20 the increase in plasminogen at follow-up is obviously affected not by variability over time but by PEA. Univariate logistic regression analysis revealed that D-dimer positivity and elevated BNP in patients at the 1-year follow-up were associated with risk for residual PH. D-dimer and BNP assessments during the postoperative follow-up after PEA are probably useful noninvasive methods for predicting residual PH. Elevated preoperative factor VIII activity was associated with perioperative death in our study. Elevated factor VIII activity was reported to be a risk factor for the occurrence of CTEPH 21 and might reflect endothelial stress and damage. Severe endothelial damage may be associated with persistent PH after PEA, resulting in perioperative death. Study Limitations The study had several limitations. First, it was a retrospective study, and excluding potential confounding between the coagulation-fibrinolysis system and pulmonary hemodynamics is difficult. Second, deaths from conditions other than CTEPH
9 978 KATO F et al. Table 7. Analysis of Prognostic Factors for Disease-Specific Survival in CTEPH Survivors of Pulmonary Endarterectomy Parameters Univariate Cox proportional hazards analysis HR 95% CI P value Data at diagnosis Age ( ) Sex (male) ( ) Coagulopathy ( ) NS APA positive ( ) NS WHO class III or IV ( ) D-dimer 1 μg/ml ( ) NS Fibrinogen ( ) NS TAT 3.0 ng/ml ( ) Factor VIII ( ) NS TM ( ) NS Plasminogen ( ) NS PIC ( ) NS PAI ( ) NS α2pi ( ) NS TPAIC ( ) NS BNP ( ) NS PaO ( ) NS Group A ( ) mpap ( ) NS Cardiac index ( ) NS PVR ( ) NS Data at follow-up within 3 months Postoperative mpap ( ) Postoperative cardiac index ( ) NS Postoperative PVR ( ) Over follow-up period Use of pulmonary vasodilators ( ) NS Continuous variables are indicated as per unit increase. HR of sex (male), WHO class ( III), and TAT positivity ( 3.0 ng/ml) were not determined because of lack of patients with these characteristics who died of CTEPH. HR, hazard ratios. Other abbreviations as in Tables 1,2. were excluded from the disease-specific survival analysis and censored at that point; however, univariate Cox proportional analysis revealed that Group A (vs. B) remained significant when deaths other than CTEPH were considered as event counts (hazard ratio [95% confidence interval ], P=0.0019; data not shown). Third, it was impossible to determine independent prognostic factors using multivariate analysis because of the improved long-term outcomes after PEA; only 6 of 102 patients died of CTEPH. Similarly, independent risk factors for residual PH at the 1-year follow-up were not identified because of the low number of study patients with residual PH. Fourth, some patients were receiving pulmonary vasodilators and all were receiving anticoagulant therapy at the time coagulation-fibrinolysis parameters were assessed. The medications might have affected these parameters. However, between the patients receiving or not receiving pulmonary vasodilators, there were no significant differences in the levels of coagulation-fibrinolysis markers, except for lower TM (4.7±2.6 vs. 6.1±3.0 FU/ml, P=0.0138) and lower TPAIC (11.9±9.7 vs. 14.0±7.0 ng/ml, P=0.0216) levels in patients receiving pulmonary vasodilators (data not shown). It is unclear if the reduced levels of fibrinolytic parameters in the patients receiving pulmonary vasodilators resulted from their clinical condition, which was severe enough to warrant the vasodilators, or from the pulmonary vasodilators. Regarding anticoagulant therapy, the proportion of patients within the therapeutic window for anticoagulant therapy (activated partial thromboplastin time 40 s, prothrombin time-international normalized ratio 1.5, or prothrombin time 18 s) was 78.3% (90 patients out of 115) at the time of preoperative blood sampling. However, the differences in the coagulation-fibrinolysis parameters of the patients within the therapeutic window and those not within the window were not significant (data not shown). Conclusions Preoperative high fibrinogen and low plasminogen values in patients with CTEPH who undergo PEA are associated with poor long-term postoperative outcome. PEA may benefit not only the pulmonary hemodynamics but also the fibrinolytic system of these patients. Grants This study was supported in part by grants from the Respiratory Failure Research Group of the Ministry of Health, Labor and Welfare of Japan, and the Pulmonary Hypertension Research Group of the Japan Agency for Medical Research and Development, AMED (K.T.), and a research grant
10 Coagulation and Fibrinolysis in Operative CTEPH 979 from the Ministry of Education, Culture, Sports, Science and Technology of Japan ( ) (N.T.). References 1. Jenkins DP, Madani M, Mayer E, Kerr K, Kim N, Klepetko W, et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2013; 41: Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation 2014; 130: Urushibara T, Tanabe N, Suda R, Kato F, Kasai H, Takeuchi T, et al. Effects of surgical and medical treatment on quality of life for patients with chronic thromboembolic pulmonary hypertension. Circ J 2015; 79: Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: Experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: Corsico AG, D Armini AM, Cerveri I, Klersy C, Ansaldo E, Niniano R, et al. Long-term outcome after pulmonary endarterectomy. Am J Respir Crit Care Med 2008; 178: Ishida K, Masuda M, Tanabe N, Matsumiya G, Tatsumi K, Nakajima N. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2012; 144: Olman MA, Marsh JJ, Lang IM, Moser KM, Binder BR, Schleef RR. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992; 86: Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90: Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Nakanishi N. Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. Chest 2003; 124: Tanabe N, Kimura A, Amano S, Okada O, Kasahara Y, Tatsumi K, et al. Association of clinical features with HLA in chronic pulmonary thromboembolism. Eur Respir J 2005; 25: Kato F, Tanabe N, Urushibara T, Kasai H, Takeuchi T, Sekine A, et al. Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension. Circ J 2014; 78: Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: Clinical picture and surgical treatment. Eur Respir J 1992; 5: Riedel M. Longterm follow-up of patients with pulmonary thromboembolism: Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982; 81: Ishida K, Masuda M, Tanaka H, Imamaki M, Katsumata M, Maruyama T, et al. Mid-term results of surgery for chronic thromboembolic pulmonary hypertension. Interact Cardiovasc Thorac Surg 2009; 9: Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 2011; 17: Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: The ADVANCE study. Diabetes 2014; 63: Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115: Pizzo SV, Schwartz ML, Hill RL, McKee PA. Mechanism of ancrod anticoagulation: A direct proteolytic effect on fibrin. J Clin Invest 1972; 51: Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93: Kostka T, Para J, Kostka B. Cardiovascular diseases (CVD) risk factors, physical activity (PA) and plasma plasminogen (Plg) in a random sample of community-dwelling elderly. Arch Gerontol Geriatr 2009; 48: Kim NH, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2012; 21: Supplementary Files Supplementary File 1 Table S1. Parameters of CTEPH patients assessed at diagnosis and at postoperative follow-up (<3 months after pulmonary endarterectomy) (n=48) Table S2. (A) Characteristics and parameters of group A and B patients who survived surgery, (B) characteristics and parameters assessed at diagnosis of all group A and B patients Figure S1. (A) Kaplan-Meier estimates of disease-specific survival in patients who survived pulmonary endarterectomy. Please find supplementary file(s);
Improved Survival in Medically Treated Chronic Thromboembolic Pulmonary Hypertension
2110 NISHIMURA R et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Pulmonary Circulation Improved Survival in Medically Treated Chronic
More informationAnn Vasc Dis Vol. 6, No. 3; 2013; pp Online August 12, Annals of Vascular Diseases doi: /avd.oa Original Article
Ann Vasc Dis Vol. 6, No. 3; 2013; pp 578 582 Online August 12, 2013 2013 Annals of Vascular Diseases doi:10.3400/avd.oa.13-00056 Original Article Respiratory and Hemodynamic Changes in Patients with Chronic
More informationORIGINAL ARTICLE. Editorial p 320. Methods. Pulmonary Circulation. 476 YAMAKI S et al.
476 YAMAKI S et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Pulmonary Circulation Histopathological Examination by Lung Biopsy
More informationPlasma Brain Natriuretic Peptide as a Noninvasive Marker for Efficacy of Pulmonary Thromboendarterectomy
Plasma Brain Natriuretic Peptide as a Noninvasive Marker for Efficacy of Pulmonary Thromboendarterectomy Noritoshi Nagaya, MD, Motomi Ando, MD, Hideo Oya, MD, Yutaka Ohkita, MD, Shingo Kyotani, MD, Fumio
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationSelection criteria for PEA (UCSD)
Chirurgische behandeling van chronische longembolen Pulmonale Thrombendarterectomie PTEA Selection criteria for PEA (UCSD) NYHA 3-4 PVR > 300 dynes.sec.cm-5 accessibility of the thrombi - strictures (main,
More informationΕπεμβατικές στρατηγικές στην πνευμονική υπέρταση
Επεμβατικές στρατηγικές στην πνευμονική υπέρταση Παναγιώτης Καρυοφύλλης Καρδιολόγος Ωνάσειο Καρδιοχειρουργικό Κέντρο Mortality in PAH 2015 ESC/ERS Guidelines. Treatment algorithm Since BAS is performed
More informationReal life management of CTEPH: patient case
2 nd International Congress on cardiovascular imaging in clinical practice k Real life management of CTEPH: patient case Anastasia Anthi Pulmonary Hypertension Clinic, Attikon University Hospital, Athens
More informationMean Pulmonary Artery Pressure Using Echocardiography in Chronic Thromboembolic Pulmonary Hypertension
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Pulmonary Circulation Mean Pulmonary Artery Pressure Using Echocardiography in Chronic
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension
REVIEW CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension David Jenkins Affiliation:
More informationMedical Therapy for Chronic Thromboembolic Pulmonary Hypertension
Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension Josanna Rodriguez-Lopez, MD Pulmonary Hypertension and Thromboendarterectomy Program Massachusetts General Hospital Harvard Medical School
More informationVascular Medicine. Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy
Vascular Medicine Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy Kurt W. Jensen, MD; Kim M. Kerr, MD; Peter F. Fedullo, MD;
More informationPulmonary Hypertension Surgical Options. Primary pulmonary hypertension. Transplantation. Thromboembolic disease Endarterectomy
Stuart W. Jamieson Cardiothoracic Surgery University of California San Diego Chronic Thromboembolic Pulmonary Hypertension Pulmonary Hypertension Surgical Options Primary pulmonary hypertension Transplantation
More informationThrombophilia and Pulmonary Endarterectomy
Prague Medical Report / Vol. 110 (2009) No. 1, p. 51 59 51) Thrombophilia and Pulmonary Endarterectomy Lindner J. 1, Jansa P. 2, Salaj P. 3, Kunstýř J. 4, Grus T. 1, Maruna P. 5, Bláha J. 4, Rubeš D. 4,
More informationQuantifying the learning curve for pulmonary thromboendarterectomy
Sihag et al. Journal of Cardiothoracic Surgery (2017) 12:121 DOI 10.1186/s13019-017-0686-1 RESEARCH ARTICLE Open Access Quantifying the learning curve for pulmonary thromboendarterectomy Smita Sihag 1,4*,
More informationPredictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension
Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension Diana Bonderman, MD; Nika Skoro-Sajer, MD; Johannes Jakowitsch, PhD; Christopher Adlbrecht, MD; Daniela Dunkler, MSc; Sharokh Taghavi,
More informationLong-term outcomes of surgery for chronic thromboembolic pulmonary hypertension compared with medical therapy at a single Korean center
ORIGINAL ARTICLE Korean J Intern Med 2017;32:855-864 https://doi.org/10.3904/kjim.2016.049 Long-term outcomes of surgery for chronic thromboembolic pulmonary hypertension compared with medical therapy
More informationPercutaneous Transluminal Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Percutaneous Transluminal Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Masaharu Kataoka, MD; Takumi Inami, MD; Kentaro Hayashida, MD; Nobuhiko Shimura, MD; Haruhisa
More informationΑγγειοπλαστική των πνευμονικών αρτηριών στην χρόνια θρομβοεμβολική πνευμονική υπέρταση. Παρόν και μέλλον
Αγγειοπλαστική των πνευμονικών αρτηριών στην χρόνια θρομβοεμβολική πνευμονική υπέρταση. Παρόν και μέλλον Παναγιώτης Καρυοφύλλης Επιμελητής Β Ωνάσειο Καρδιοχ/κό Κέντρο CTEPH is an obstructive disease Pulmonary
More informationChronic post-embolic pulmonary hypertension: a new target for medical therapies?
REVIEW RARE DISEASE AND ORPHAN DRUGS Chronic post-embolic pulmonary hypertension: a new target for medical therapies? Marion Delcroix Affiliations: Respiratory Division, University Hospitals and Dept of
More informationFrom Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension
From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension Dr Rachel Davies Respiratory Physician National Pulmonary Hypertension Service Hammersmith Hospital Royal College of Physicians
More informationChronic Thromboembolic Pulmonary Hypertension Complicated by a Cavitating Lung Infection Caused by Mycobacterium intracellulare
CASE REPORT Chronic Thromboembolic Pulmonary Hypertension Complicated by a Cavitating Lung Infection Caused by Mycobacterium intracellulare Kenichi Okuda, Hirotoshi Matsui, Junko Suzuki, Nobuharu Ohshima,
More informationChronic thromboembolic pulmonary hypertension in pediatric patients
Chronic thromboembolic pulmonary hypertension in pediatric patients Michael M. Madani, MD, a Lara M. Wittine, MD, b William R. Auger, MD, b Peter F. Fedullo, MD, b Kim M. Kerr, MD, b Nick H. Kim, MD, b
More informationThe efficacy of pulmonary thromboendarterectomy on long-term gas exchange
Eur Respir J 1997; 10: 2066 2072 DOI: 10.1183/09031936.97.10092066 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 The efficacy of pulmonary
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care providers who can contribute to screening and early detection of CTEPH among
More informationPulmonary Artery Diameter Predicts Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Artery Diameter Predicts Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension Summary Koichi Sugimoto, 1,2 MD, Kazuhiko Nakazato, 1 MD,
More informationSevere pulmonary embolism: surgical aspects. Oliver Reuthebuch Clinic for Cardiac Surgery University Hospital Basel Switzerland
Severe pulmonary embolism: surgical aspects Oliver Reuthebuch Clinic for Cardiac Surgery University Hospital Basel Switzerland Severe pulmonary embolism Acute pulmonary embolism Chronic pulmonary thromboembolism
More informationDISTAL PULMONARY THROMBOENDARTERECTOMY: IS IT WORTH IT?
DISTAL PULMONARY THROMBOENDARTERECTOMY: IS IT WORTH IT? Bob Moraca, MD Associate Professor of Surgery Surgical Director of The CTEPH Program Director of Thoracic Aortic and Arrhythmia Surgery Allegheny
More informationManaging chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Eur Respir Rev 2009; 18: 111, 24 28 DOI: 10.1183/09059180.00011110 CopyrightßERSJ Ltd 2009 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options I.M. Lang ABSTRACT:
More informationSurgical Management in Chronic Thromboembolic Pulmonary Hypertension. Michael Bates, MD, FACS Ochsner Health System, New Orleans, LA
Surgical Management in Chronic Thromboembolic Pulmonary Hypertension Michael Bates, MD, FACS Ochsner Health System, New Orleans, LA Disclosures No industry conflicts I am a surgeon and always disclose
More informationLearning Objectives. Outline. CTEPH: Practice Guidelines. History. 36 y/o Man with Chest Pain and Dyspnea
Learning Objectives By the end of this activity, the participant should be better able to: Identify risk factors and early signs of chronic thromboembolic pulmonary hypertension (CTEPH) among post-pulmonary
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationPulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension
REVIEW CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension David Jenkins 1, Michael Madani 2, Elie Fadel 3, Andrea
More informationPulmonary hypertension in sarcoidosis
Pulmonary hypertension in sarcoidosis Olivier SITBON Centre de Référence de l Hypertension Pulmonaire Sévère Hôpital Universitaire de Bicêtre INSERM U999 Université Paris-Sud Le Kremlin-Bicêtre France
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationWHAT IS. Helping your patients understand their type of PH. Educational program by. Material endorsed by
Educational program by Material endorsed by WHAT IS CTEPH Helping your patients understand their type of PH Provided by Bayer to help education of the PH community What is ph? B lood travels from your
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationSerum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension*
CHEST Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* Anna Fijalkowska, MD; Marcin Kurzyna, MD; Adam Torbicki, MD; Grzegorz Szewczyk, MD; Michał
More informationChronic Thromboembolic Pulmonary Hypertension Lara M. Wittine, MD William R. Auger, MD *
Current Treatment Options in Cardiovascular Medicine (2010) 12:131 141 DOI 10.1007/s11936-010-0062-0 Vascular Disease Chronic Thromboembolic Pulmonary Hypertension Lara M. Wittine, MD William R. Auger,
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationChronic Thromboembolic Pulmonary Hypertension Associated with Chronic Inflammation
CASE REPORT Chronic Thromboembolic Pulmonary Hypertension Associated with Chronic Inflammation Naoyuki Kuse 1,2, Shinji Abe 1, Hidehiko Kuribayashi 1, Asami Fukuda 1, Yuji Kusunoki 1, Ritsuko Narato 1,
More informationThe classification of pulmonary hypertension. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Eur Respir Rev 2010; 19: 115, 59 63 DOI: 10.1183/09059180.00007309 CopyrightßERSJ Ltd 2010 REVIEW Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology M. Humbert*,#,"
More informationWHAT IS CTEPH. Helping you understand your type of PH. Provided by Bayer to help education of the PH community
Educational program by Material endorsed by WHAT IS CTEPH Helping you understand your type of PH Provided by Bayer to help education of the PH community WHAT IS PH? lood travels from your heart to the
More informationPulmonary Endarterectomy: Assessment of Operability, Surgical Description, and Post-op Care
Pulmonary Endarterectomy: Assessment of Operability, Surgical Description, and Post-op Care David Poch, MD Division of Pulmonary and Critical Care University of California San Diego La Jolla, CA Victor
More informationChapter 8. F.A. Klok, K.W. van Kralingen, A.P.J. van Dijk, F.H. Heyning, H.W. Vliegen and M.V. Huisman. Haematologica 2009; in press
Chapter 8 Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism F.A. Klok, K.W. van Kralingen, A.P.J. van Dijk,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationWHAT IS CTEPH. Helping you understand your type of PH. Provided by Bayer to help education of the PH community
Educational program by Material endorsed by WHAT IS CTEPH Helping you understand your type of PH Provided by Bayer to help education of the PH community WHAT IS PH? lood travels from your heart to the
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationPulmonary Endarterectomy Improves Dyspnea by the Relief of Dead Space Ventilation
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationCTEPH. surgical treatment. Ph. Dartevelle, E. Fadel, S. Mussot, D. Fabre, O. Mercier and G. Simonneau PARIS-SUD UNIVERSITY
CTEPH surgical treatment Ph. Dartevelle, E. Fadel, S. Mussot, D. Fabre, O. Mercier and G. Simonneau MARIE-LANNELONGUE HOSPITAL BICETRE HOSPITAL PARIS-SUD UNIVERSITY Clinical Classification of PH G Simonneau
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationMedical Management of CTEPH: What is its role?
Medical Management of CTEPH: What is its role? Nick H. Kim, MD University of California, San Diego Disclosures Consultant/Speakers Bureau: Actelion, Bayer Healthcare Research Support: Aires, Gilead Sciences,
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationState-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management
Eur Respir Rev 2012; 21: 123, 32 39 DOI: 10.1183/09059180.00009211 CopyrightßERS 2012 REVIEW State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management D. Jenkins*, E. Mayer
More informationAssociation of clinical features with HLA in chronic pulmonary thromboembolism
Eur Respir J 2005; 25: 131 138 DOI: 10.1183/09031936.04.00042304 CopyrightßERS Journals Ltd 2005 Association of clinical features with HLA in chronic pulmonary thromboembolism N. Tanabe*, A. Kimura #,",
More informationPulmonary arterial compliance and exercise capacity after pulmonary endarterectomy
ORIGINAL ARTICLE PULMONARY VASCULAR DISEASES Pulmonary arterial compliance and exercise capacity after pulmonary endarterectomy Stefano Ghio 1, Marco Morsolini 2, Angelo Corsico 3, Catherine Klersy 4,
More informationPulmonary Thromboembolectomy in Congenital Antithrombin III Deficiency Associated with Acute Pulmonary Embolism Report of a Case
Case Report Pulmonary Thromboembolectomy in Congenital Antithrombin III Deficiency Associated with Acute Pulmonary Embolism Report of a Case Junichiro Takahashi, MD, 1 Masamichi Ito, MD, 1 Jun Okude, MD,
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationPulmonary Hypertension: Evolution and
Management of Pulmonary Hypertension: Evolution and Controversies VERMONT CARDIAC NETWORK SPRING CONFERENCE MAY 10, 2018 MARYELLEN ANTKOWIAK, MD, PULMONARY & CRITICAL CARE MEDICINE, UVMMC WHO classification
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationRISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain Potential Conflicts of Interest Financial conflicts of
More information*Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors James R Klinger,* Raymond
More informationGender Is a Significant Factor Affecting Blood Coagulation Systems
Showa Univ J Med Sci 29 2, 151 162, June 2017 Original Gender Is a Significant Factor Affecting Blood Coagulation Systems Koichiro INOKUCHI, Taku ASANO, Akinori OCHI, Toshihiko GOKAN, Kosuke YOSHIKAWA,
More informationPulmonary thromboendarterectomy (PTE) is indicated for
Pulmonary Thromboendarterectomy Steven R. Meyer, MD, PhD, and Christopher G.A. McGregor, MB, FRCS, MD (Hons) Division of Cardiovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota.
More informationLong-Term Recovery of Exercise Ability After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension
Long-Term Recovery of Exercise Ability After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension Hitoshi Matsuda, MD, Hitoshi Ogino, MD, Kenji Minatoya, MD, Hiroaki Sasaki, MD, Norifumi
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationIs the percutaneous approach the future?
Chronic ThromboEmbolic Pulmonary Hypertension Is the percutaneous approach the future? Dr Hélène Bouvaist Cardiology Department Thorax Center Grenoble -France Mr R, 75 years old Dyspnea NYHA 4 Heart failure,
More informationEvaluating the Post Pulmonary Embolism Patient: What You Need to Know
Friday CME Breakfast Evaluating the Post Pulmonary Embolism Patient: What You Need to Know Dustin Fraidenburg, MD Assistant Professor Director, Pulmonary Hypertension Program Department of Medicine Division
More informationSerum Soluble Thrombomodulin Level on Admission Is a Useful Predictor of Treatment Response in Patients with Acute Pulmonary Thromboembolism
Showa Univ J Med Sci 29 1, 79 86, March 2017 Original Serum Soluble Thrombomodulin Level on Admission Is a Useful Predictor of Treatment Response in Patients with Acute Pulmonary Thromboembolism Taiju
More informationChronic thromboembolic pulmonary hypertension (CTEPH)
Sequential Hybrid Therapy With Pulmonary Endarterectomy and Additional Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Kenichi Yanaka, MD; Kazuhiko Nakayama, MD, PhD; Toshiro
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationBlood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.
Blood clotting It is the conversion, catalyzed by thrombin, of the soluble plasma protein fibrinogen (factor I) into polymeric fibrin, which is deposited as a fibrous network in the primary thrombus. Thrombin
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationRisk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease
Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationΚαθετηριασμός δεξιάς κοιλίας. Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ
Καθετηριασμός δεξιάς κοιλίας Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ The increasing interest in pulmonary arterial hypertension (PAH), the increasing interest in implantation of LVADs, and the evolution
More informationDisclosures. Anesthesia for Endovascular Treatment of Acute Ischemic Stroke. Acute Ischemic Stroke. Acute Stroke = Medical Emergency!
Disclosures Anesthesia for Endovascular Treatment of Acute Ischemic Stroke I have nothing to disclose. Chanhung Lee MD, PhD Associate Professor Anesthesia and perioperative Care Acute Ischemic Stroke 780,000
More informationΕιδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών
Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών . Updated Clinical Classification of Pulmonary Hypertension
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationCHAPTER X - SECONDARY PULMONARY HYPERTENSION CHRONIC PULMONARY THROMBOEMBOLISM (HTP). PULMONARY THROMBENDARTERECTOMY
CHAPTER X - SECONDARY PULMONARY HYPERTENSION CHRONIC PULMONARY THROMBOEMBOLISM (HTP). PULMONARY THROMBENDARTERECTOMY Walter KLEPETKO, PhD, VIENNA - AUSTRIA Marian GASPAR, PhD, TIMISOARA 10. 1. Definition.
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationChronic thromboembolic pulmonary hypertension (CTEPH) and the essential role of imaging specialists PP-ADE-ALL
Chronic thromboembolic pulmonary hypertension (CTEPH) and the essential role of imaging specialists PP-ADE-ALL-0086-2 CTEPH and the essential role of imaging specialists 1 Introduction, and signs, symptoms
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationThe Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy
The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy Michael M Madani, MD, FACS Professor & Chief, Cardiovascular & Thoracic Surgery Director, UCSD - Surgery University of California San Diego
More informationAbstract Book. Inspiring Approaches to Clinical Challenges in Pulmonary Hypertension
Inspiring Approaches to Clinical Challenges in Pulmonary Hypertension Abstract Book A symposium sponsored by Bayer Schering Pharma at ERS 2008 Annual Congress www.ventavis.com Welcome Dear Colleague, It
More informationPatricia A. Thistlethwaite, MD, PhD, Aaron Kemp, BA, Lingling Du, MD, Michael M. Madani, MD, and Stuart W. Jamieson, MB, FRCS
Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension Patricia A. Thistlethwaite, MD, PhD, Aaron Kemp, BA, Lingling Du, MD, Michael M. Madani, MD, and Stuart
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationNHS England. Evidence review: Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
NHS England Evidence review: Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) 1 NHS England Evidence review: Balloon pulmonary angioplasty for inoperable
More informationPulmonary Arterial Hypertension: Biomarkers and Treatment
Pulmonary Arterial Hypertension: Biomarkers and Treatment Demos Papamatheakis, MD Assistant Clinical Professor Division of Pulmonary, Critical Care and Sleep Medicine UC San Diego Health Definition EHJ
More informationPrecision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
1. Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the
More information